Johns Hopkins ABX Guide
Bezlotoxumab
INDICATIONS
FDA
FDA
Reduce the recurrence of Clostridium difficile infections (CDIs) in patients 18 years of age and older who are receiving antibacterial CDI drug treatment and are at high risk for CDI recurrence.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: March 4, 2018
Citation
Dzintars, Kathryn. "Bezlotoxumab." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540676/all/Bezlotoxumab.
Dzintars K. Bezlotoxumab. Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540676/all/Bezlotoxumab. Accessed November 28, 2023.
Dzintars, K. (2018). Bezlotoxumab. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540676/all/Bezlotoxumab
Dzintars K. Bezlotoxumab [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. [cited 2023 November 28]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540676/all/Bezlotoxumab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Bezlotoxumab
ID - 540676
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2018/03/04/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540676/all/Bezlotoxumab
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
